Stage IV Fallopian Tube Cancer AJCC v8 Clinical Trials

19 clinical trials for Stage IV Fallopian Tube Cancer AJCC v8 across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax — RECRUITING · PHASE1
• Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers — RECRUITING · PHASE1
• Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial — RECRUITING · PHASE3
• Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer — RECRUITING · PHASE1
• An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study — RECRUITING · NA
• Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 — ACTIVE_NOT_RECRUITING · PHASE1
• National Cancer Institute "Cancer Moonshot Biobank" — ACTIVE_NOT_RECRUITING
• Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients — COMPLETED · NA
• Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis — COMPLETED · PHASE1
• Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — WITHDRAWN · PHASE1
• ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer — WITHDRAWN · PHASE1
• Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer — WITHDRAWN · PHASE1

Refine this search